Evaluation of Sunitinib Malate in Patients With Von Hippel-Lindau Syndrome (VHL) Who Have VHL Lesions to Follow

PHASE2TerminatedINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

May 31, 2006

Primary Completion Date

May 31, 2011

Study Completion Date

May 31, 2011

Conditions
Von Hippel-Lindau SyndromeRenal Cell CarcinomaHemangioblastoma
Interventions
DRUG

SU011248

50 mg/day orally for 4 weeks, no treatment for 2 weeks (6 weeks = 1 cycle).

Trial Locations (1)

77030

UT MD Anderson Cancer Center, Houston

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Pfizer

INDUSTRY

lead

M.D. Anderson Cancer Center

OTHER